Search alternatives:
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
significant barrier » significant burden (Expand Search)
significant cause » significant change (Expand Search), significant changes (Expand Search), significant gap (Expand Search)
Showing 481 - 500 results of 21,342 for search '(( ((significant cause) OR (significant barrier)) decrease ) OR ( significant decrease decrease ))', query time: 0.49s Refine Results
  1. 481
    RSV test results (N = 268).

    RSV test results (N = 268). by Reem Eid (20889732)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  2. 482
    summary of the confidence intervals.

    summary of the confidence intervals. by Yohannis Derbew Molla (16471771)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  3. 483
    Evolution of health burden and life expectancy under different expenditure scenarios.

    Evolution of health burden and life expectancy under different expenditure scenarios. by Margherita Molaro (17803989)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  4. 484
    Capabilities expansion scenarios considered. <i><i>g</i></i><sub>GDP</sub> and <i><i>g</i></i><sub>fHE</sub> refer to the growth rate of annual GDP (in constant 2015 US$) and growth rate of fraction of GDP allocated to health (<i><i>f</i></i><sub>HE</sub>) assumed, leading to a yearly expenditure growth per scenario of [(1 + <i><i>g</i></i><sub>GDP</sub>) × (1 + <i><i>g</i></i><sub>fHE</sub>) − 1]. The normalised health expenditure (NHE) associated with each scenario (defined in

    Capabilities expansion scenarios considered. <i><i>g</i></i><sub>GDP</sub> and <i><i>g</i></i><sub>fHE</sub> refer to the growth rate of annual GDP (in constant 2015 US$) and growt... by Margherita Molaro (17803989)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  5. 485
    Scaling of overall health burden with yearly expenditure growth.

    Scaling of overall health burden with yearly expenditure growth. by Margherita Molaro (17803989)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  6. 486
    Impact on different areas of health.

    Impact on different areas of health. by Margherita Molaro (17803989)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  7. 487
    Summary of Pooled Estimates and Heterogeneity for Key Variables.

    Summary of Pooled Estimates and Heterogeneity for Key Variables. by Yohannis Derbew Molla (16471771)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  8. 488
    PRISMA flowchart of the study selection process.

    PRISMA flowchart of the study selection process. by Yohannis Derbew Molla (16471771)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  9. 489
    Fer-1 alleviated liver lesions caused by <i>C. sinensis.</i>

    Fer-1 alleviated liver lesions caused by <i>C. sinensis.</i> by Haoyang Zhang (1706815)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  10. 490
    Inhibition of ferroptosis alleviated liver fibrosis caused by <i>C. sinensis.</i>

    Inhibition of ferroptosis alleviated liver fibrosis caused by <i>C. sinensis.</i> by Haoyang Zhang (1706815)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  11. 491
    ALKG1202R –ABT199 interactions.

    ALKG1202R –ABT199 interactions. by Richard Junior Zapata Dongo (17912565)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  12. 492
    ALKC1156Y –ABT199 interactions.

    ALKC1156Y –ABT199 interactions. by Richard Junior Zapata Dongo (17912565)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  13. 493
    S1 Data -

    S1 Data - by Richard Junior Zapata Dongo (17912565)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  14. 494
    Combination therapy exhibited apoptosis in Ba/F3 EML4-ALKmutant cell models.

    Combination therapy exhibited apoptosis in Ba/F3 EML4-ALKmutant cell models. by Richard Junior Zapata Dongo (17912565)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  15. 495
    Ba/F3 EML4-ALK<sup>mutants</sup> exhibit variable dose-response to ABT-199 treatment.

    Ba/F3 EML4-ALK<sup>mutants</sup> exhibit variable dose-response to ABT-199 treatment. by Richard Junior Zapata Dongo (17912565)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  16. 496
    Molecular docking showed that ABT-199 can fit into active site of ALK<sup>Mutant</sup>.

    Molecular docking showed that ABT-199 can fit into active site of ALK<sup>Mutant</sup>. by Richard Junior Zapata Dongo (17912565)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  17. 497
    The binding energy values of ATP, ALK inhibitors and ABT-199 to ALK were obtained from AlphaFold and modeled protein structures.

    The binding energy values of ATP, ALK inhibitors and ABT-199 to ALK were obtained from AlphaFold and modeled protein structures. by Richard Junior Zapata Dongo (17912565)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  18. 498
    Amino acids interactions and binding energy describe that ABT-199 binds to ALK<sup>Mutant</sup>.

    Amino acids interactions and binding energy describe that ABT-199 binds to ALK<sup>Mutant</sup>. by Richard Junior Zapata Dongo (17912565)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  19. 499
    Western blot analysis of drug combinations.

    Western blot analysis of drug combinations. by Richard Junior Zapata Dongo (17912565)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  20. 500
    ALKL1196M –ABT199 interactions.

    ALKL1196M –ABT199 interactions. by Richard Junior Zapata Dongo (17912565)

    Published 2025
    Subjects:
    Save to List
    Saved in:

Search Tools: